Vancomycin targets bacterial cell wall synthesis. Specifically, it binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing transpeptidation and ultimately inhibiting cell wall formation. This leads to bacterial cell lysis and death. Its mechanism differs significantly from that of β-lactam antibiotics, making it a valuable option for treating infections caused by bacteria resistant to those drugs.
Spectrum of Activity
Vancomycin’s primary use lies in treating serious infections caused by Gram-positive bacteria. These include Staphylococcus aureus (including methicillin-resistant S. aureus or MRSA), Streptococcus pneumoniae, and Enterococcus species. However, its activity against Gram-negative bacteria is limited. Dosage and duration of treatment vary depending on the infection’s severity and the patient’s clinical condition; consult current guidelines for precise recommendations.
Clinical Applications
Clinicians frequently prescribe vancomycin for severe infections like bloodstream infections, pneumonia, endocarditis, and osteomyelitis caused by susceptible Gram-positive organisms. It’s also used prophylactically in high-risk situations, such as before certain surgeries to prevent infections. Remember to always consider potential drug interactions and monitor for adverse effects such as nephrotoxicity and ototoxicity. Regular monitoring of serum levels is recommended to ensure therapeutic efficacy and minimize toxicity.
Considerations for Use
Resistance to vancomycin is a growing concern. The emergence of vancomycin-resistant Enterococci (VRE) and vancomycin-intermediate S. aureus (VISA) necessitates careful antibiotic stewardship. Appropriate antibiotic selection should be guided by susceptibility testing and local epidemiology data. Accurate diagnosis is paramount before initiating vancomycin therapy. Inappropriate use contributes to antibiotic resistance and should be avoided.
